Alnylam Pharmaceuticals
ALNY
#548
Rank
HK$292.56 B
Marketcap
HK$2,260
Share price
2.60%
Change (1 day)
89.93%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total debt

Total debt on the balance sheet as of December 2024 : HK$10.07 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's total debt is HK$10.07 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Alnylam Pharmaceuticals - Total debt on balance sheet (from 2003 to 2024)

Total debt by year

Year Total debt Change
2024-12-31HK$10.06 B-1.31%
2023-12-31HK$10.19 B-1.17%
2022-12-31HK$10.31 B32.61%
2021-12-31HK$7.77 B92.53%
2020-12-31HK$4.04 B70.75%
2019-12-31HK$2.36 B907.21%
2018-12-31HK$0.23 B0.23%
2017-12-31HK$0.23 B-79.85%
2016-12-31HK$1.16 B
2007-12-31HK$52.69 M-25.84%
2006-12-31HK$71.05 M23.93%
2005-12-31HK$57.33 M2.46%
2004-12-31HK$55.96 M288.36%
2003-12-31HK$14.4 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
HK$4.08 B-59.47%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$21.02 B 108.66%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$10.44 B 3.63%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$3.92 B-61.08%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$2.13 M-99.98%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$243.00 B 2,311.79%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
HK$144.85 B 1,337.70%๐Ÿ‡ซ๐Ÿ‡ท France
HK$140.54 B 1,294.93%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel